ID   RELB_HUMAN              Reviewed;         579 AA.
AC   Q01201; Q6GTX7; Q9UEI7;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   04-APR-2006, sequence version 2.
DT   28-JUN-2023, entry version 209.
DE   RecName: Full=Transcription factor RelB;
DE   AltName: Full=I-Rel;
GN   Name=RELB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=T-cell;
RX   PubMed=1577270; DOI=10.1101/gad.6.5.745;
RA   Ruben S.M., Klement J.F., Maher M., Coleman T.A., Chen C.H., Rosen C.A.;
RT   "I-Rel: a novel rel-related protein that inhibits NF-kappa B
RT   transcriptional activity.";
RL   Genes Dev. 6:745-760(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Yoshiura K., Murray J.C.;
RT   "A transcriptional map in the region of 19q13 derived using direct
RT   sequencing and exon trapping.";
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND IDENTIFICATION IN THE NF-KAPPA-B RELB-P50 COMPLEX.
RX   PubMed=1732739; DOI=10.1128/mcb.12.2.674-684.1992;
RA   Ryseck R.P., Bull P., Takamiya M., Bours V., Siebenlist U., Dobrzanski P.,
RA   Bravo R.;
RT   "RelB, a new Rel family transcription activator that can interact with p50-
RT   NF-kappa B.";
RL   Mol. Cell. Biol. 12:674-684(1992).
RN   [6]
RP   FUNCTION.
RX   PubMed=8441398; DOI=10.1128/mcb.13.3.1572-1582.1993;
RA   Dobrzanski P., Ryseck R.P., Bravo R.;
RT   "Both N- and C-terminal domains of RelB are required for full
RT   transactivation: role of the N-terminal leucine zipper-like motif.";
RL   Mol. Cell. Biol. 13:1572-1582(1993).
RN   [7]
RP   FUNCTION, IDENTIFICATION IN THE NF-KAPPA-B RELB-P50 COMPLEX, AND
RP   IDENTIFICATION IN THE NF-KAPPA-B RELB-P52 COMPLEX.
RX   PubMed=7925301; DOI=10.1002/j.1460-2075.1994.tb06782.x;
RA   Dobrzanski P., Ryseck R.P., Bravo R.;
RT   "Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha
RT   determine pools of constitutive and inducible NF-kappa B activity.";
RL   EMBO J. 13:4608-4616(1994).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37 AND SER-573, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20873783; DOI=10.1021/pr100562w;
RA   Vaz Meirelles G., Ferreira Lanza D.C., da Silva J.C., Santana Bernachi J.,
RA   Paes Leme A.F., Kobarg J.;
RT   "Characterization of hNek6 interactome reveals an important role for its
RT   short N-terminal domain and colocalization with proteins at the
RT   centrosome.";
RL   J. Proteome Res. 9:6298-6316(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   FUNCTION, AND INDUCTION BY NUPR1.
RX   PubMed=22565310; DOI=10.1172/jci60144;
RA   Hamidi T., Algul H., Cano C.E., Sandi M.J., Molejon M.I., Riemann M.,
RA   Calvo E.L., Lomberk G., Dagorn J.C., Weih F., Urrutia R., Schmid R.M.,
RA   Iovanna J.L.;
RT   "Nuclear protein 1 promotes pancreatic cancer development and protects
RT   cells from stress by inhibiting apoptosis.";
RL   J. Clin. Invest. 122:2092-2103(2012).
RN   [13]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-16, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [14]
RP   FUNCTION, INVOLVEMENT IN IMD53, AND VARIANT IMD53 397-TYR--THR-579 DEL.
RX   PubMed=26385063; DOI=10.1016/j.jaut.2015.09.001;
RA   Sharfe N., Merico D., Karanxha A., Macdonald C., Dadi H., Ngan B.,
RA   Herbrick J.A., Roifman C.M.;
RT   "The effects of RelB deficiency on lymphocyte development and function.";
RL   J. Autoimmun. 65:90-100(2015).
CC   -!- FUNCTION: NF-kappa-B is a pleiotropic transcription factor which is
CC       present in almost all cell types and is involved in many biological
CC       processed such as inflammation, immunity, differentiation, cell growth,
CC       tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric
CC       complex formed by the Rel-like domain-containing proteins RELA/p65,
CC       RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at
CC       kappa-B sites in the DNA of their target genes and the individual
CC       dimers have distinct preferences for different kappa-B sites that they
CC       can bind with distinguishable affinity and specificity. Different dimer
CC       combinations act as transcriptional activators or repressors,
CC       respectively. NF-kappa-B is controlled by various mechanisms of post-
CC       translational modification and subcellular compartmentalization as well
CC       as by interactions with other cofactors or corepressors. NF-kappa-B
CC       complexes are held in the cytoplasm in an inactive state complexed with
CC       members of the NF-kappa-B inhibitor (I-kappa-B) family. In a
CC       conventional activation pathway, I-kappa-B is phosphorylated by I-
CC       kappa-B kinases (IKKs) in response to different activators,
CC       subsequently degraded thus liberating the active NF-kappa-B complex
CC       which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50
CC       and RelB-p52 complexes are transcriptional activators. RELB neither
CC       associates with DNA nor with RELA/p65 or REL. Stimulates promoter
CC       activity in the presence of NFKB2/p49. As a member of the
CC       NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal
CC       adenocarcinoma with remarkable resistance to cell stress, such as
CC       starvation or gemcitabine treatment. Regulates the circadian clock by
CC       repressing the transcriptional activator activity of the CLOCK-BMAL1
CC       heterodimer in a CRY1/CRY2 independent manner. Increased repression of
CC       the heterodimer is seen in the presence of NFKB2/p52. Is required for
CC       both T and B lymphocyte maturation and function (PubMed:26385063).
CC       {ECO:0000269|PubMed:1732739, ECO:0000269|PubMed:22565310,
CC       ECO:0000269|PubMed:26385063, ECO:0000269|PubMed:7925301,
CC       ECO:0000269|PubMed:8441398}.
CC   -!- SUBUNIT: Component of the NF-kappa-B RelB-p50 complex. Component of the
CC       NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to
CC       be transient and may prevent degradation allowing for heterodimer
CC       formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and
CC       NFKB2/p100. Interacts with NFKBID. Interacts with BMAL1 and the
CC       interaction is enhanced in the presence of CLOCK (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q01201; Q8N668: COMMD1; NbExp=2; IntAct=EBI-357837, EBI-1550112;
CC       Q01201; P49841: GSK3B; NbExp=4; IntAct=EBI-357837, EBI-373586;
CC       Q01201; P19838: NFKB1; NbExp=5; IntAct=EBI-357837, EBI-300010;
CC       Q01201; Q00653: NFKB2; NbExp=2; IntAct=EBI-357837, EBI-307326;
CC       Q01201; Q04206-2: RELA; NbExp=2; IntAct=EBI-357837, EBI-289947;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20873783}. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:20873783}. Note=Colocalizes with NEK6 in the
CC       centrosome.
CC   -!- INDUCTION: Up-regulated by mitogens and NUPR1.
CC       {ECO:0000269|PubMed:22565310}.
CC   -!- DOMAIN: Both N- and C-terminal domains are required for transcriptional
CC       activation.
CC   -!- PTM: Phosphorylation at 'Thr-103' and 'Ser-573' is followed by
CC       proteasomal degradation. {ECO:0000250}.
CC   -!- DISEASE: Immunodeficiency 53 (IMD53) [MIM:617585]: An autosomal
CC       recessive primary immunodeficiency apparent from early infancy and
CC       resulting in recurrent infections, severe autoimmune skin disease
CC       rheumatoid arthritis, and failure to thrive. Immunologic workup shows
CC       increased CD4+/CD8+ ratio, impaired T-cell proliferative response to
CC       multiple antigen, T-cell developmental and functional defects, and
CC       impaired ability to produce specific immunoglobulins.
CC       {ECO:0000269|PubMed:26385063}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- CAUTION: Was originally thought to inhibit the transcriptional activity
CC       of nuclear factor NF-kappa-B. {ECO:0000305|PubMed:1577270}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/324/RELB";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M83221; AAA36127.1; -; mRNA.
DR   EMBL; AF043463; AAC82346.1; -; Genomic_DNA.
DR   EMBL; AF043454; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043455; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043456; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043457; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043458; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043459; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043460; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043461; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; AF043462; AAC82346.1; JOINED; Genomic_DNA.
DR   EMBL; DQ314887; ABC40746.1; -; Genomic_DNA.
DR   EMBL; BC028013; AAH28013.1; -; mRNA.
DR   CCDS; CCDS46110.1; -.
DR   PIR; A42617; A42617.
DR   RefSeq; NP_006500.2; NM_006509.3.
DR   AlphaFoldDB; Q01201; -.
DR   SMR; Q01201; -.
DR   BioGRID; 111903; 74.
DR   ComplexPortal; CPX-5831; NF-kappaB DNA-binding transcription factor complex, p52/RelB.
DR   ComplexPortal; CPX-5833; NF-kappaB DNA-binding transcription factor complex, p50/RelB.
DR   CORUM; Q01201; -.
DR   DIP; DIP-27531N; -.
DR   IntAct; Q01201; 45.
DR   MINT; Q01201; -.
DR   STRING; 9606.ENSP00000221452; -.
DR   ChEMBL; CHEMBL4523273; -.
DR   GlyGen; Q01201; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q01201; -.
DR   PhosphoSitePlus; Q01201; -.
DR   BioMuta; RELB; -.
DR   DMDM; 92090634; -.
DR   EPD; Q01201; -.
DR   jPOST; Q01201; -.
DR   MassIVE; Q01201; -.
DR   MaxQB; Q01201; -.
DR   PaxDb; Q01201; -.
DR   PeptideAtlas; Q01201; -.
DR   ProteomicsDB; 57938; -.
DR   Antibodypedia; 3573; 733 antibodies from 43 providers.
DR   DNASU; 5971; -.
DR   Ensembl; ENST00000221452.13; ENSP00000221452.7; ENSG00000104856.15.
DR   GeneID; 5971; -.
DR   KEGG; hsa:5971; -.
DR   MANE-Select; ENST00000221452.13; ENSP00000221452.7; NM_006509.4; NP_006500.2.
DR   UCSC; uc060zvi.1; human.
DR   AGR; HGNC:9956; -.
DR   CTD; 5971; -.
DR   DisGeNET; 5971; -.
DR   GeneCards; RELB; -.
DR   HGNC; HGNC:9956; RELB.
DR   HPA; ENSG00000104856; Low tissue specificity.
DR   MalaCards; RELB; -.
DR   MIM; 604758; gene.
DR   MIM; 617585; phenotype.
DR   neXtProt; NX_Q01201; -.
DR   OpenTargets; ENSG00000104856; -.
DR   PharmGKB; PA34322; -.
DR   VEuPathDB; HostDB:ENSG00000104856; -.
DR   eggNOG; ENOG502QV8A; Eukaryota.
DR   GeneTree; ENSGT00940000160230; -.
DR   InParanoid; Q01201; -.
DR   OMA; NQYREGA; -.
DR   OrthoDB; 1059550at2759; -.
DR   PhylomeDB; Q01201; -.
DR   TreeFam; TF325632; -.
DR   PathwayCommons; Q01201; -.
DR   Reactome; R-HSA-5607761; Dectin-1 mediated noncanonical NF-kB signaling.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5676590; NIK-->noncanonical NF-kB signaling.
DR   SignaLink; Q01201; -.
DR   SIGNOR; Q01201; -.
DR   BioGRID-ORCS; 5971; 22 hits in 1173 CRISPR screens.
DR   ChiTaRS; RELB; human.
DR   GeneWiki; RELB; -.
DR   GenomeRNAi; 5971; -.
DR   Pharos; Q01201; Tbio.
DR   PRO; PR:Q01201; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q01201; protein.
DR   Bgee; ENSG00000104856; Expressed in granulocyte and 98 other tissues.
DR   ExpressionAtlas; Q01201; baseline and differential.
DR   Genevisible; Q01201; HS.
DR   GO; GO:0000785; C:chromatin; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0071159; C:NF-kappaB complex; NAS:ComplexPortal.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:CACAO.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0017053; C:transcription repressor complex; IDA:UniProtKB.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0019882; P:antigen processing and presentation; IEA:Ensembl.
DR   GO; GO:0071470; P:cellular response to osmotic stress; IEA:Ensembl.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0030098; P:lymphocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IMP:CACAO.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; NAS:ComplexPortal.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0034097; P:response to cytokine; IBA:GO_Central.
DR   GO; GO:0045063; P:T-helper 1 cell differentiation; IEA:Ensembl.
DR   CDD; cd01177; IPT_NFkappaB; 1.
DR   CDD; cd07886; RHD-n_RelB; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   Gene3D; 2.60.40.340; Rel homology domain (RHD), DNA-binding domain; 1.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_dom.
DR   InterPro; IPR033926; IPT_NFkappaB.
DR   InterPro; IPR000451; NFkB/Dor.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR032399; RelB_leu_zip.
DR   InterPro; IPR030496; RelB_RHD_N.
DR   InterPro; IPR032400; RelB_transact.
DR   InterPro; IPR030492; RHD_CS.
DR   InterPro; IPR032397; RHD_dimer.
DR   InterPro; IPR011539; RHD_DNA_bind_dom.
DR   InterPro; IPR037059; RHD_DNA_bind_dom_sf.
DR   PANTHER; PTHR24169; NUCLEAR FACTOR NF-KAPPA-B PROTEIN; 1.
DR   PANTHER; PTHR24169:SF18; TRANSCRIPTION FACTOR RELB; 1.
DR   Pfam; PF16180; RelB_leu_zip; 1.
DR   Pfam; PF16181; RelB_transactiv; 1.
DR   Pfam; PF16179; RHD_dimer; 1.
DR   Pfam; PF00554; RHD_DNA_bind; 1.
DR   PRINTS; PR00057; NFKBTNSCPFCT.
DR   SMART; SM00429; IPT; 1.
DR   SUPFAM; SSF81296; E set domains; 1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   PROSITE; PS01204; REL_1; 1.
DR   PROSITE; PS50254; REL_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Biological rhythms; Cytoplasm; Cytoskeleton; Disease variant;
KW   DNA-binding; Methylation; Nucleus; Phosphoprotein; Reference proteome;
KW   Repressor; Transcription; Transcription regulation.
FT   CHAIN           1..579
FT                   /note="Transcription factor RelB"
FT                   /id="PRO_0000205173"
FT   DOMAIN          125..440
FT                   /note="RHD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00265"
FT   REGION          1..39
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          40..68
FT                   /note="Leucine-zipper"
FT   MOTIF           433..438
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         16
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         37
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         573
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   VARIANT         396
FT                   /note="T -> M (in dbSNP:rs770682728)"
FT                   /id="VAR_051782"
FT   VARIANT         397..579
FT                   /note="Missing (in IMD53)"
FT                   /evidence="ECO:0000269|PubMed:26385063"
FT                   /id="VAR_079201"
FT   CONFLICT        139
FT                   /note="R -> P (in Ref. 1; AAA36127)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        411
FT                   /note="R -> A (in Ref. 1; AAA36127)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   579 AA;  62134 MW;  C2C61C2C8640513E CRC64;
     MLRSGPASGP SVPTGRAMPS RRVARPPAAP ELGALGSPDL SSLSLAVSRS TDELEIIDEY
     IKENGFGLDG GQPGPGEGLP RLVSRGAASL STVTLGPVAP PATPPPWGCP LGRLVSPAPG
     PGPQPHLVIT EQPKQRGMRF RYECEGRSAG SILGESSTEA SKTLPAIELR DCGGLREVEV
     TACLVWKDWP HRVHPHSLVG KDCTDGICRV RLRPHVSPRH SFNNLGIQCV RKKEIEAAIE
     RKIQLGIDPY NAGSLKNHQE VDMNVVRICF QASYRDQQGQ MRRMDPVLSE PVYDKKSTNT
     SELRICRINK ESGPCTGGEE LYLLCDKVQK EDISVVFSRA SWEGRADFSQ ADVHRQIAIV
     FKTPPYEDLE IVEPVTVNVF LQRLTDGVCS EPLPFTYLPR DHDSYGVDKK RKRGMPDVLG
     ELNSSDPHGI ESKRRKKKPA ILDHFLPNHG SGPFLPPSAL LPDPDFFSGT VSLPGLEPPG
     GPDLLDDGFA YDPTAPTLFT MLDLLPPAPP HASAVVCSGG AGAVVGETPG PEPLTLDSYQ
     APGPGDGGTA SLVGSNMFPN HYREAAFGGG LLSPGPEAT
//
